Evaluation of Arthralgia Induced by Aromatase Inhibitor Therapy

Year 2013, Volume: 38 Issue: 1, 78 - 85, 01.03.2013

Gulabi Meşe Hakan Sakallı Didem Arslan Taş Abdullah Canataroğlu

Abstract

Background: In breast cancer treatment, aromatase inhibitors (AI) and tamoxifen (Tmx) are frequently used. In this study, the relationship between the hormonal therapy and arthralgia in women with breast cancer was studied. Methods: Sixty-four patients of whom 32 taking AI and 32 taking Tmx were included into the study. VAS was used to determine the intensity of pain. Also five options Likert scale was applied to all patients to answer the question "what are your thoughts about the sources of your current pain?". As laboratory parameters, CBC, BUN creatinine, ALT, AST, alkaline phosphatase, calcium, CRP, ESR, ANA, RF, and estradiol levels of the patients were analyzed. Results: The mean age of the AI group was 52.7 ± 8.2 years and in the Tmx group, it was 47.4 ± 6.5 years (p

Keywords

Aromatase inhibitors, Arthralgia, Breast Cancer, Tamoxifen, Likert scale

Aromataz İnhibitörleri Tarafından İndüklenen Artraljinin Değerlendirilmesi

Abstract

Amaç: Meme kanseri hormon tedavisinde, aromataz inhibitörleri (AI) ve (Tamoksifen) Tmx sık olarak kullanılmaktadır. Bu çalışmada, meme kanserli kadınlarda görülen artralji yakınmalarının hormon tedavisinde kullanılan ajanlarla ilişkisi araştırılmıştır. Yöntem: Meme kanseri olan ve AI grubu ilaç alan 32 hasta ve Tmx alan 32 hasta çalışmaya dahil edildi. Hastaların eklem ağrılarının şiddetini belirlemek için Görsel Analog Skalası (VAS) kullanıldı. Yine tüm hastalara „mevcut eklem ağrılarınızın kaynağı hakkındaki nedenlerle ilgili düşünceniz nedir?‟ sorusuna cevap arayan beş seçenekli Likert ölçeği uygulandı. Laboratuar parametresi olarak, hastaların CBC, BUN, kreatinin, ALT, AST, alkalen fosfataz, kalsiyum, CRP, ESR, ANA, Anti-DNA, RF, östradiol seviyelerine bakıldı. Bulgular: AI kullanan hasta grubun yaş ortalaması 52,7±8,2 yıl, Tmx kullanan grubun yaş ortalaması 47,4±6,5 yıl idi (p

Keywords

Aromataz inhibitörleri, artralji, meme kanseri, Tamoksifen, Likert skalası

References

• Crew, K.D., H. Greenlee, J. Capodice, G. Raptis, L. Brafman, et al.Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007; 25. 3877-83.
• Cline, M.E., J. Herman, E.R. Shaw, and R.D. Morton.Standardization of the visual analogue scale. Nurs Res. 1992; 41: 378-80.
• Collins, S.L., R.A. Moore, and H.J. McQuay.The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain. 1997; 72: 95-7.
• Dawes, J.Do Data Characteristics Change According to the Number of Scale Points Used? International Journal of Market Research. 2008; 50: 61-77.
• Cohen L, M.L., Morrison K., Research Methods in Education. London: RoutledgeFalmer. 2007; 325-8.
• Coombes, R.C., L.S. Kilburn, C.F. Snowdon, R. Paridaens, R.E. Coleman, et al.Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007; 369: 559-70.
• Howell A, C.J., Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS.Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 60-2.
• Muss, H.B., D. Tu, J.N. Ingle, S. Martino, N.J. Robert, et al.Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008; 26: 1956-64.
• Burstein, H.J.Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007; 16: 223-34.
• Sestak, I., J. Cuzick, F. Sapunar, R. Eastell, J.F. Forbes, et al.Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008; 9: 866-72.
• Richette, P., M. Corvol, and T. Bardin.Estrogens, cartilage, and osteoarthritis. Joint Bone Spine. 2003; 70: 257-62.
• Ushiyama, T., H. Ueyama, K. Inoue, I. Ohkubo, and S. Hukuda.Expression of genes for estrogen receptors alpha and beta in human articular chondrocytes. Osteoarthritis Cartilage. 1999; 7: 560-6.
• Dieppe, P.A. and L.S. Lohmander.Pathogenesis and management of pain in osteoarthritis. Lancet. 2005; 365: 965
• Smith, Y.R., C.S. Stohler, T.E. Nichols, J.A. Bueller, R.A. Koeppe, et al.Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci 2006; 26: 5777-85.
• Friedman, A.J., M. Juneau-Norcross, and M.S. Rein.Adverse effects of leuprolide acetate depot treatment. Fertil Steril. 1993; 59: 448-50.
• Morales, L., S. Pans, K. Verschueren, B. Van Calster, R. Paridaens, et al.Prospective Study to Assess Short-Term Intra-Articular and Tenosynovial Changes in the Aromatase Inhibitor–Associated Arthralgia Syndrome. Journal of Clinical Oncology. 2008; 26: 3147-52.
• Dennerstein L, L.P., Koochaki PE, Graziottin A, Leiblum S, Alexander JL.A symptomatic approach to understanding women's health experiences: a cross-cultural comparison of women aged 20 to 70 years. Menopause. 2007; 14: 688-96.
• Cooper C, I.H., Croft P.Individual risk factors for hiposteoarthritis: obesity, hip injury, and physical activity. Am J Epidemiol. 1998; 147: 516-22.
• Zumoff B., Relationship of obesity to blood estogens Cancer Res. 1982; 42: 3289-94.
• Yazışma Adresi / Address for Correspondence: Dr. Didem Arslan Taş Cukurova University Internal Medicine and Rheumatology Deparment ADANA e-mail: [e-mail] geliş tarihi/received :19.06.2012 kabul tarihi/accepted:21.07.2012